Colon Cancer Clinical Trial
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Summary
This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
Full Description
Upon determination of eligibility, patients will be receive:
Topotecan
Eligibility Criteria
Inclusion Criteria:
To be included in this study, you must meet the following criteria:
Metastatic colorectal cancer
One previous chemotherapy for metastatic disease
Measurable or evaluable disease
Able to perform activities of daily living with assistance
Adequate bone marrow, liver, and kidney function
All patients must give written informed consent prior to study entry.
Exclusion Criteria:
You cannot participate in this study if any of the following apply to you:
Brain or meningeal involvement
Serious active infection or underlying medical conditions
Other active neoplasms are ineligible
Pregnant or lactating
Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Nashville Tennessee, 37203, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.